Predictive and Prognostic Potentials of Lymphocyte-C-Reactive Protein Ratio Upon Hospitalization in Adult Patients with Acute Pancreatitis

J Inflamm Res. 2024 Mar 13:17:1659-1669. doi: 10.2147/JIR.S450587. eCollection 2024.

Abstract

Purpose: In this study, our objective was to investigate the potential utility of lymphocyte-C-reactive protein ratio (LCR) as a predictor of disease progression and a screening tool for intensive care unit (ICU) admission in adult patients with acute pancreatitis (AP).

Methods: We included a total of 217 adult patients with AP who were admitted to the First Affiliated Hospital of Harbin Medical University between July 2019 and June 2022. These patients were categorized into three groups: mild AP (MAP), moderately severe AP (MSAP), and severe AP (SAP), based on the presence and duration of organ dysfunction. Various demographic and clinical data were collected and compared among different disease severity groups.

Results: Height, diabetes, lymphocyte count (LYMPH), lymphocyte percentage (LYM%), platelet count (PLT), D-Dimer, albumin (ALB), blood urea nitrogen (BUN), serum creatinine (SCr), glucose (GLU), calcium ion (Ca2+), C-reactive protein (CRP), procalcitonin (PCT), hospitalization duration, ICU admission, need for BP, LCR, sequential organ failure assessment (SOFA) score, bedside index for severity in AP (BISAP) score, and modified Marshall score showed significant differences across different disease severity groups upon hospitalization. Notably, there were significant differences in LCR between the MAP group and the MSAP and SAP combined group, and the MAP and MSAP combined group and the SAP group, and adult AP patients with ICU admission and those without ICU admission upon hospitalization.

Conclusion: In summary, LCR upon hospitalization can be utilized as a simple and reliable predictor of disease progression and a screening tool for ICU admission in adult patients with AP.

Keywords: C-reaction protein; ICU admission; acute pancreatitis; disease progression; lymphocyte count; lymphocyte-C-reactive protein ratio; screening tool.

Grants and funding

This work was supported by the National Natural Science Foundation of China (82372172), the Key research and development plan project of Heilongjiang Province (GA23C007), Heilongjiang Province Postdoctoral Start-up Fund (LBH-Q20037), Special Fund for Clinical Research of Wu Jie-ping Medical Foundation (320.6750.2022-02-16), the Research Project of Heilongjiang Provincial Health Commission (20231717010461), the Scientific Research Innovation Fund of the First Affiliated Hospital of Harbin Medical University (2021M08).